BioCentury
ARTICLE | Clinical News

Agennix plummets on talactoferrin news

August 8, 2012 12:31 AM UTC

Agennix AG (Xetra:AGX) slid EUR 1.28 (69%) to EUR 0.57 on Tuesday after saying it will discontinue the Phase III FORTIS-C trial of oral talactoferrin as a first-line treatment for non-small cell lung cancer. The news follows an announcement late Monday that the recombinant human lactoferrin (rhLF) missed the primary endpoint of median overall survival (OS) in the Phase III FORTIS-M trial in third-line NSCLC. ...